Company intelligence / Profile preview

Ciba-Geigy

Ownership: Private
Development stage: Commercial

Overview

Ciba-Geigy developed and commercialized numerous blockbuster drugs, including diclofenac (Voltaren), carbamazepine (Tegretol), imipramine (Tofranil), and the nicotine patch Habitrol/Nicotinell. Their drugs reached global markets and demonstrated efficacy and safety in large patient populations by the 1980s and 1990s[1][2][3].

Therapeutic areas: PsychiatryImmunologyNeurologyCardiovascularHematology
Modalities: Small moleculeBiologic
Industry: Pharma

Drug pipeline

2 assets

ledermycin

Commercial

1 more asset in the full pipeline.

Request access →

Partnerships

ETH ZurichUniversity of BaselCollaborations with several US and European pharma companies in steroid chemistry[4]

Beyond the preview

Go deeper on Ciba-Geigy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ciba-Geigy.

Explore the full profile